ARTICLE | Company News

Kuros reverse-merges with Cytos

December 4, 2015 2:47 AM UTC

Kuros Biosurgery AG (Zurich, Switzerland) plans to make its debut on the SIX Swiss Exchange through a reverse merger with Cytos Biotechnology AG (SIX:CYTN). The combined entity will be Kuros Biosciences AG.

Kuros' management team, including CEO Didier Cowling, will lead the merged company. Cytos Chairman and CEO Christian Itin will be chairman. Existing Kuros shareholders will own about four-fifths of the company, while Cytos shareholders will hold the balance. ...